cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Celldex Therapeutics Inc
7 own
25 watching
Current Price
$51.88
$3.82
(7.95%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
0
52-Week High
52-Week High
52.99000
52-Week Low
52-Week Low
22.11000
Average Volume
Average Volume
3.17M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization0
icon52-Week High52.99000
icon52-Week Low22.11000
iconAverage Volume3.17M
iconDividend Yield--
iconP/E Ratio--
What does the Celldex Therapeutics Inc do?
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers. In addition, the company focuses on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases, such as CDX-0158, a humanized monoclonal antibody currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors and other KIT positive tumors; and CDX-3379, a human monoclonal antibody, which has completed a Phase 1b study in patients with solid tumors. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company is headquartered in Hampton, New Jersey.
Read More
How much money does Celldex Therapeutics Inc make?
News & Events about Celldex Therapeutics Inc.
Globe Newswire
8 months ago
- Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition to a historically limited treatment landscape -- At week 24, 55% of all patients with CSU in the 1.5 mg/kg, 3.0 mg/kg and 4.5 mg/kg dose groups had complete response (UAS7) and 69% had well-...
Globe Newswire
11 months ago
HAMPTON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30th at 11:30 am ET. A webcast of the ...
Globe Newswire
1 year ago
- Rapid, profound and durable responses across multiple dosing groups with favorable safety profile observedpositioning barzolimab as a potential best-in-class addition to a historically limited treatment landscape -- At week 12, 56% of all patients in the 1.5 mg/kg, 3.0 mg/kg and 4.5 mg/kg dose ...
Globe Newswire
1 year ago
Company to host webcast on Sunday, February 26 at 4:00 pm CT/5:00 pm ETHAMPTON, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that data from the Companys Phase 1b multi-dose study of barzolvolimab in chronic spontaneous urticaria will be presented ...
Frequently Asked Questions
Frequently Asked Questions
What is Celldex Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Celldex Therapeutics Inc shares?
plus_minus_icon
How can I buy Celldex Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Celldex Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Celldex Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Celldex Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Celldex Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Celldex Therapeutics Inc?
plus_minus_icon
What percentage is Celldex Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Celldex Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$51.88
$3.82
(7.95%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00